Treatment of cutaneous leishmaniasis in Saudi Arabia.
D000965:Antimony / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007896:Leishmaniasis / Q000188:drug therapy*; D008297:Male; D009942:Organometallic Compounds; D012293:Rifampin / Q000627:therapeutic use; D004113:Succimer / Q000627:therapeutic use
D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D000965:Antimony; C004443:stibocaptate; D004113:Succimer; D012293:Rifampin